Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma

Utilization and costs of epidermal growth factor receptor mutation testing and targeted therapy in Medicare patients with metastatic lung adenocarcinoma

Abstract Background Guidelines in 2013 and 2014 recommended Epidermal Growth Factor Receptor (EGFR) testing for metastatic lung adenocarcinoma patients as the efficacy of targeted therapies depends on the mutations. However, adherence to these guidelines and the corresponding costs have not been wel...

Full description

Bibliographic Details
Main Authors: Chan Shen, Rolfy A. Perez Holguin, Eric Schaefer, Shouhao Zhou, Chandra P. Belani, Patrick C. Ma, Michael F. Reed
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Health Services Research
Subjects:
EGFR mutation testing
Targeted therapy
SEER-Medicare database
Adenocarcinoma
Online Access:https://doi.org/10.1186/s12913-022-07857-y

Internet

https://doi.org/10.1186/s12913-022-07857-y

Similar Items